MarketPulse

mNEXSPIKE

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi

Sanofi's Nuvaxovid Outperforms Moderna mRNA Vaccine in Tolerability Study

Sanofi's Nuvaxovid shows 50% fewer severe side effects than Moderna's mRNA vaccine in clinical trial, with patients twice as likely to choose it again.
SNYMRNAclinical trialCOVID-19 vaccine
BenzingaBenzinga··Vandana Singh

BioNTech Sues Moderna Over Patent Rights to Next-Gen COVID Vaccine

BioNTech sues Moderna for patent infringement over next-gen COVID vaccine technology, claiming mNEXSPIKE violates its spike protein patents. Seeking damages for unlicensed use.
PFEMRNABNTXintellectual propertymRNA technology